Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models.
Lélu K, Dubois C, Evlachev A, Crausaz M, Baldazza M, Kehrer N, Brandely R, Schlesinger Y, Silvestre N, Marchand JB, Bastien B, Leung-Theung-Long S, Unsinger J, Martin P, Inchauspé G. Lélu K, et al. Among authors: martin p. J Immunol. 2022 Jul 1;209(1):99-117. doi: 10.4049/jimmunol.2101145. Epub 2022 Jun 6. J Immunol. 2022. PMID: 35667841
Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
Martin P, Parroche P, Pajot A, Chatel L, Barreto C, Touat L, Dubois V, Rohrlich PS, Bain C, Trépo C, Negro F, Inchauspé G, Fournillier A. Martin P, et al. Microbes Infect. 2006 Aug;8(9-10):2432-41. doi: 10.1016/j.micinf.2006.05.006. Epub 2006 Jun 30. Microbes Infect. 2006. PMID: 16859951 Free article.
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G. Fournillier A, et al. Among authors: martin p. Vaccine. 2007 Oct 16;25(42):7339-53. doi: 10.1016/j.vaccine.2007.08.020. Epub 2007 Aug 31. Vaccine. 2007. PMID: 17875349
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G. Martin P, et al. Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26. Gut. 2015. PMID: 25429051 Free PMC article.
A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. Kratzer R, et al. Among authors: martin p. Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29388874 Free PMC article.
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G. Zoulim F, et al. Among authors: martin p. Hum Vaccin Immunother. 2020;16(2):388-399. doi: 10.1080/21645515.2019.1651141. Epub 2019 Oct 4. Hum Vaccin Immunother. 2020. PMID: 31373537 Free PMC article. Clinical Trial.
7,908 results